Success of Face Analysis Technology in Rare Genetic Diseases Diagnosed by Whole-Exome Sequencing: A Single-Center Experience.
Artificial intelligence
Deep learning
Whole-exome sequencing
Journal
Molecular syndromology
ISSN: 1661-8769
Titre abrégé: Mol Syndromol
Pays: Switzerland
ID NLM: 101525192
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
accepted:
04
12
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
ppublish
Résumé
The diagnosis of rare genetic diseases is one of the most difficult areas in medicine. Whole-exome sequencing (WES) technology makes it easier to diagnose these diseases. In addition, next-generation phenotyping can help to diagnose computer-based algorithms. Detailed dysmorphologic findings of 25 patients diagnosed by WES in our center were described. The success of this technology in diagnosing rare genetic diseases was investigated by scanning the photographs of 25 patients with Face2Gene application. The application listed possible preliminary diagnoses (30 disease suggestion). Of these, 12 (48%) cases were correctly matched. The most common disease group in the patients was neurological disease (96%). The most common mode of inheritance in the patients was autosomal recessive. The rate of consanguineous marriages was determined in 80% of the patients. Ten patients had microcephaly and 7 patients had corpus callosum anomaly. In our study, we found that the success of Face2Gene was lower than described in the literature. We think that the probable cause of this condition is that the cases are very rare, and there is not enough data about these diseases in the application. Therefore, it is recommended that applications should be used more frequently by pediatricians and clinical geneticists. The diagnosis of rare diseases still is quite difficult. Nowadays, WES is a successful method. However, applications such as Face2Gene help to make a clinical prediagnosis and create a larger database.
Identifiants
pubmed: 32256296
doi: 10.1159/000505800
pii: msy-0011-0004
pmc: PMC7109386
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4-14Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Genet Med. 2011 Sep;13(9):841-7
pubmed: 21555946
Nature. 2009 Sep 10;461(7261):272-6
pubmed: 19684571
Am J Hum Genet. 1988 May;42(5):677-93
pubmed: 3358420
Brain. 2014 Jun;137(Pt 6):1579-613
pubmed: 24477430
JAMA. 2014 Nov 12;312(18):1870-9
pubmed: 25326635
Ann Neurol. 2014 Oct;76(4):473-83
pubmed: 25131622
Nat Genet. 2003 Mar;33 Suppl:228-37
pubmed: 12610532
Am J Med Genet A. 2008 Oct 1;146A(19):2501-11
pubmed: 18792984
J Hum Genet. 2019 Aug;64(8):789-794
pubmed: 31138847
Hum Mol Genet. 2010 Oct 15;19(R2):R119-24
pubmed: 20846941
Nat Med. 2019 Jan;25(1):60-64
pubmed: 30617323
Dev Med Child Neurol. 2014 Aug;56(8):732-41
pubmed: 24617602
J Inherit Metab Dis. 2018 May;41(3):533-539
pubmed: 29623569
Am J Med Genet A. 2009 Jan;149A(1):2-5
pubmed: 19127575
Neurology. 2009 Sep 15;73(11):887-97
pubmed: 19752457
Genet Med. 1999 Jul-Aug;1(5):207-12
pubmed: 11256674
Elife. 2014 Jun 24;3:e02020
pubmed: 24963138
Acta Paediatr Scand. 1991 Jan;80(1):106-9
pubmed: 2028781
Arch Dis Child. 2007 Dec;92(12):1120-6
pubmed: 18032641
NPJ Genom Med. 2018 Jul 9;3:16
pubmed: 30002876
Sociol Health Illn. 2005 Jul;27(5):551-74
pubmed: 16078901
J Biosoc Sci. 2015 Nov;47(6):718-26
pubmed: 25630711
Genet Med. 2016 Nov;18(11):1090-1096
pubmed: 26938784
Clin Chem. 2016 Nov;62(11):1458-1464
pubmed: 27630156
Nat Rev Genet. 2013 Oct;14(10):681-91
pubmed: 23999272